Seagen (NASDAQ: SGEN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Seagen Return vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Seagen Company Info
Seagen is a biotechnology company that develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
News & Analysis
Here are the five best biotech ETFs to invest in right now.
Investors are cheering Pfizer's planned acquisition of Seagen.
Rumors of another buyout are pushing the drugmaker's shares higher today.
Investors and analysts liked what they heard in the company's Q4 update.
These stocks may soon start turning heads with their revenue growth.
These stocks aren't bargain buys just yet, but they could be soon.
It's growing faster than competitors, but headwinds might soon bog it down.
The billionaire investor is a big believer in betting on America.
SGEN earnings call for the period ending December 31, 2022.
SGEN earnings call for the period ending September 30, 2022.
SGEN earnings call for the period ending June 30, 2022.
SGEN earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.